Although breathing is an involuntary, automatic process, for many people it can be difficult. Chronic obstructive pulmonary disease (COPD) is a serious illness that prevents normal lung function, and its early onset in adults can be caused by deficiency of alpha1antitrypsin (AATD), a genetic disorder.1 More than 185,000 people are living with severe AATD worldwide.2 As a pioneer and leader in alpha1-antitrypsin treatment (AAT), we are looking to expand our reach and administration options for patients with this condition to help reduce the rate of COPD mortality.
- Alternative delivery options for AAT
Continuing our commitment to patients with AATD, we are researching more convenient routes of administration, such as subcutaneous and inhaled delivery alternatives.
- Expanding AAT into new indications
We have a dedicated focus on expanding AAT treatment to additional pulmonology indications beyond emphysema, such as non–cystic fibrosis bronchiectasis.
It took me 21 years for a correct diagnosis of AATD. I am finishing my seventh year of infusions and have never missed one. I am on my feet and moving most of the time.
1 de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med. 2014;276(4):311-35. doi: 10.1111/joim.12239
2 Grifols Investor Relations, 2021 Investor and Analyst Day
KEY THERAPEUTIC AREAS
Patients are at the center of our far-ranging scientific research to develop therapeutic solutions to some of the world’s most pressing healthcare challenges.